BioTuesdays

HCW starts Kiadis Pharma at buy

H.C. Wainwright has launched coverage of Kiadis Pharma NV (NXT AM:KDS) of Amsterdam with a “buy” rating and price target of €15. The stock closed at €10 on Friday.“We view Kiadis as an innovator in hematopoietic stem...

HCW assumes coverage of Galmed at buy

H.C. Wainwright analyst, Ed Arce, has assumed coverage of Galmed Pharmaceuticals (NASDAQ:GLMD) with a “buy” rating and $22 price target. The stock closed at $4.44 on Friday.Galmed is focused on the development of a sole...

TransEnterix updates SurgiBot FDA submission

TransEnterix (NYSE MKT:TRXC) has received an update from the FDA on the status of the 510(k) submission for its robotics SurgiBot system to improve minimally invasive surgery.The FDA advised the company that it has not...

Piper Jaffray starts Inogen at neutral

Piper Jaffray has initiated coverage of Inogen (NASDAQ:INGN) with a “neutral” rating and price target of $46. The stock closed at $41.07 on Wednesday.“We truly appreciate the unique technology the company has developed...

Leerink starts Depomed at outperform

Leerink Partners has initiated coverage of Depomed (NASDAQ:DEPO) with an “outperform” rating and $21 price target. The stock closed at $14.62 on Wednesday.“Depomed’s Nucynta for chronic pain provides a differentiated...

Subscribe

Sign up to our weekly BioTuesdays newsletter.